Section Arrow
Quote
AARD.NASDAQ
- Aardvark Therapeutics Inc
Quotes are at least 15-min delayed:2025/12/25 21:21 EST
Regular Hours
Last
 14.26
+0.11 (+0.78%)
Day High 
14.6092 
Prev. Close
14.15 
1-M High
16 
Volume 
63.75K 
Bid
14.26
Ask
14.34
Day Low
14 
Open
14.15 
1-M Low
9.18 
Market Cap 
308.09M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.18 
20-SMA 12.75 
50-SMA 11.71 
52-W High 19.58 
52-W Low 4.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.53/-2.82
Enterprise Value
308.53M
Balance Sheet
Book Value Per Share
5.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
APLTApplied Therapeutics0.1154-0.0003-0.26%-- 
INDPIndaptus Therapeutics Inc2.65+0.7+35.90%-- 
OMEROmeros Corp15.36+6.61+75.54%-- 
DRMADermata Therapeutics Inc2.37+0.33+16.18%0.13PE
CTXRCitius Pharmaceuticals Inc0.8006-0.2394-23.02%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.